Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B
- 280 Downloads
Insulin resistance and protein tyrosine phosphatase 1B (PTP1B) overexpression are strongly associated with type 2 diabetes mellitus (T2DM), which is characterized by defects in insulin signaling and glucose intolerance. In a previous study, we demonstrated oligonol inhibits PTP1B and α-glucosidase related to T2DM. In this study, we examined the molecular mechanisms underlying the anti-diabetic effects of oligonol in insulin-resistant HepG2 cells. Glucose uptake was assessed using a fluorescent glucose tracer, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxyglucose, and the signaling pathway was investigated by western blotting. Oligonol significantly increased insulin-provoked glucose uptake and decreased PTP1B expression, followed by modulation of ERK phosphorylation. In addition, oligonol activated insulin receptor substrate 1 by reducing phosphorylation at serine 307 and increasing that at tyrosine 895, and enhanced the phosphorylations of Akt and phosphatidylinositol 3-kinase. Interestingly, it also reduced the expression of two key enzymes of gluconeogenesis (glucose 6-phosphatase and phosphoenolpyruvate carboxykinase), attenuated oxidative stress by scavenging/inhibiting peroxynitrite, and reactive oxygen species (ROS) generation, and augmented the expression of nuclear factor kappa B. These findings suggest oligonol improved the insulin sensitivity of insulin-resistant HepG2 cells by attenuating the insulin signaling blockade and modulating glucose uptake and production. Furthermore, oligonol attenuated ROS-related inflammation and prevented oxidative damage in our in vitro model of type 2 diabetes. These result indicate oligonol has promising potential as a treatment for T2DM.
KeywordsProtein tyrosine phosphatase 1B Diabetes mellitus Insulin-resistant HepG2 cells Oligonol Glucose uptake Insulin signaling
Compliance with ethical standards
Conflict of interest
J. S. Choi is a Consultant for Amino Up Chemical Co. Ltd., which partly funded this research, and provided the test material, Oligonol. H. Fujii and A. Sato are in an employment relationship with the Amino Up Chemical Co. Ltd. H. A. Jung, T. Yokozawa, C. H. Park, H. K. Bhakta and P. Paudel state that there are no conflicts of interest.
- Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH (2000) Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 20:5479–5489CrossRefPubMedPubMedCentralGoogle Scholar
- Nonaka GI, Sun B, Yuan L, Nakagawa T, Fujii H, Surh YJ. Sulfur containing proanthocyanidin oligomer composition and process for producing the same. International Patent Application No. WO/2004/103988 A1Google Scholar
- Ragheb R, Shanab GM, Medhat AM, Seoudi DM, Adeli K, Fantus IG (2009) Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem Biophys Res Commun 389:211–216CrossRefPubMedPubMedCentralGoogle Scholar
- Takada M, Sumi M, Maeda A, Watanabe F, Kamiya T, Ishii T, Nakano M, Akagawa M (2012) Pyrroloquinoline quinone, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves impaired glucose tolerance in diabetic KK-A(y) mice. Biochem Biophys Res Commun 428:315–320CrossRefPubMedGoogle Scholar
- Tanaka T, Yoshitake N, Zhao P, Matsuo Y, Kouno I, Nonaka GI (2007) Production of oligomeric proanthocyanidins by fragmentation of polymers. Jpn J Food Chem 14:134Google Scholar
- Zabolotny JM, Haj FG, Kim YB, Kim HJ, Shulman GI, Kim JK, Neel BG, Kahn BB (2004) Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem 279:24844–24851CrossRefPubMedGoogle Scholar